Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 11:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 340 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: tenofovir/emtricitabine (TDF/FTC) Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Feasibility of Short-Term PrEP Uptake for MSM With Episodic High-Risk for HIV

NCT02495779
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
emtricitabine/tenofovir, CBT-based counseling
Drug · Behavioral
Lead sponsor
James Egan
Other
Eligibility
18 Years and older · Male only
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
2
States / cities
Boston, Massachusetts • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 27, 2019 · Synced Oct 14, 2026, 11:23 PM EDT
Completed Phase 1 Interventional Results available

Body Compartment PK for New HIV Pre-exposure Prophylaxis Modalities

NCT02985996
View directory record Official record
Conditions
HIV Infections
Interventions
Truvada, Genvoya
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 49 Years · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Oct 14, 2026, 11:23 PM EDT
Terminated Phase 2 Interventional Results available

A Pharmacodynamic Study to Evaluate the Effect of a Fixed Dose Combination Pill on Blood Pressure

NCT01005290
View directory record Official record
Conditions
Hypertension
Interventions
Combination pill, Ramipril
Drug
Lead sponsor
Ferrer Internacional S.A.
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 26, 2012 · Synced Oct 14, 2026, 11:23 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF

NCT05911360
View directory record Official record
Conditions
HIV, HIV Infections
Interventions
DTG/3TC
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
50 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
24
States / cities
Phoenix, Arizona • Bakersfield, California • Palm Springs, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 14, 2026, 11:23 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

DOT Diary Optimization Pilot: A Pilot Study to Optimize the DOT Diary App to Measure PrEP Adherence

NCT03387462
View directory record Official record
Conditions
Adherence, Medication, Risk Behavior, Pre-Exposure Prophylaxis, HIV Prevention
Interventions
Emtricitabine / Tenofovir Disoproxil Oral Tablet, DOT Diary mobile app
Drug · Other
Lead sponsor
Public Health Foundation Enterprises, Inc.
Other
Eligibility
18 Years to 35 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
San Francisco, California • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Oct 14, 2026, 11:23 PM EDT
Completed No phase listed Observational

Cellular Pharmacology and Platelet Effects of Abacavir and Lamivudine Anabolites

NCT04301661
View directory record Official record
Conditions
HIV-1-infection
Interventions
Blood collection, Abacavir/lamivudine, Tenofovir alafenamide/emtricitabine, Switch
Other · Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 99 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 9, 2023 · Synced Oct 14, 2026, 11:23 PM EDT
Not listed Phase 4 Interventional

Effect of Biktarvy & Symtuza on microRNAs in HIV and Correlation With Weight Gain

NCT05463783
View directory record Official record
Conditions
HIV Infections, Obesity
Interventions
Biktarvy, Symtuza
Drug
Lead sponsor
East Carolina University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Oct 14, 2026, 11:23 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients

NCT01495702
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, HIV Infections
Interventions
NNRTI, FTC/TDF, Stribild
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
439 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
39
States / cities
Phoenix, Arizona • Beverly Hills, California • Hayward, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2016 · Synced Oct 14, 2026, 11:23 PM EDT
Completed Phase 3 Interventional Results available

Efavirenz or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir Disoproxil Fumarate or Abacavir/Lamivudine in HIV Infected Treatment-Naive Adults

NCT00118898
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir/Lamivudine, Atazanavir, Efavirenz, Emtricitabine/Tenofovir disoproxil fumarate, Ritonavir, Abacavir/Lamivudine placebo, Emtricitabine/Tenofovir disoproxil fumarate placebo
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
16 Years and older
Enrollment
1,864 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
51
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2018 · Synced Oct 14, 2026, 11:23 PM EDT
Completed Phase 3 Interventional Results available

Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz Versus Combivir/Efavirenz in Antiretroviral-Naive HIV-1 Infected Subjects

NCT00112047
View directory record Official record
Conditions
HIV Infections
Interventions
Emtricitabine (FTC), Tenofovir Disoproxil Fumarate (TDF), Efavirenz (EFV), FTC/TDF, FTC/TDF/EFV, Lamivudine/zidovudine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
517 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
5
States / cities
Beverly Hills, California • Washington D.C., District of Columbia • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2010 · Synced Oct 14, 2026, 11:23 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Biobehavioral Interventions for HIV-negative, Stimulant Using Men Who Have Sex With Men

NCT01140880
View directory record Official record
Conditions
HIV Seroconversion, Stimulant Abuse
Interventions
Truvada
Drug
Lead sponsor
Friends Research Institute, Inc.
Other
Eligibility
18 Years and older · Male only
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Oct 14, 2026, 11:23 PM EDT
Completed Phase 2 Interventional

A Study to Compare Anti-HIV Drugs Given Twice a Day or Once a Day, With or Without Direct Observation

NCT00036452
View directory record Official record
Conditions
HIV Infections
Interventions
lopinavir/ritonavir, emtricitabine, stavudine, tenofovir DF
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
27
States / cities
Los Angeles, California • Sacramento, California • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 14, 2026, 11:23 PM EDT
Completed Phase 4 Interventional

Rapid Reinitiation of a Single Tablet Antiretroviral Therapy Using Symtuza® in HIV-1 Infected Treatment-Experienced Patients Off Therapy. (ReSTART)

NCT04388904
View directory record Official record
Conditions
HIV-1-infection
Interventions
Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (FDC)
Drug
Lead sponsor
The Crofoot Research Center, Inc.
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 26, 2024 · Synced Oct 14, 2026, 11:23 PM EDT
Completed Not applicable Interventional Results available

Safety and Effectiveness of Short-Term Anti-HIV Drug Therapy for Recent HIV-1 Infection

NCT00414518
View directory record Official record
Conditions
HIV Infections
Interventions
Tenofovir disoproxil fumarate/Emtricitabine, Lopinavir/Ritonavir
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Denver, Colorado • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 20, 2013 · Synced Oct 14, 2026, 11:23 PM EDT
Completed Phase 3 Interventional Results available

Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)

NCT04223791
View directory record Official record
Conditions
HIV Infection
Interventions
DOR/ISL, BIC/FTC/TAF, Placebo to BIC/FTC/TAF, Placebo to FDC DOR/ISL
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
28
States / cities
Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 14, 2026, 11:23 PM EDT
Completed Phase 3 Interventional Results available

Comparative Study of Three NNRTI-Sparing HAART Regimens

NCT00811954
View directory record Official record
Conditions
HIV Infection
Interventions
Emtricitabine/tenofovir disoproxil fumarate, Raltegravir, Darunavir, Ritonavir, Atazanavir
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
1,814 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
55
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 39 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2014 · Synced Oct 14, 2026, 11:23 PM EDT
Completed Phase 2 Interventional Results available

Dose Ranging, Switch Study of Islatravir (MK-8591) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013]

NCT04564547
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Islatravir, Ulonivirine, BIC/FTC/TAF, Placebo to ISL, Placebo to Ulonivirine, Placebo to BIC/FTC/TAF
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
10
States / cities
Phoenix, Arizona • Los Angeles, California • Ft. Pierce, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 14, 2026, 11:23 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evaluating the Safety and Tolerability of Antiretroviral Drug Regimens Used as Pre-Exposure Prophylaxis to Prevent HIV Infection in At-Risk Men Who Have Sex With Men and in At-Risk Women

NCT01505114
View directory record Official record
Conditions
HIV Infection
Interventions
Maraviroc, Emtricitabine, Tenofovir disoproxil fumarate, Maraviroc placebo, Emtricitabine placebo, Tenofovir disoproxil fumarate placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
594 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 14, 2026, 11:23 PM EDT
Completed Phase 4 Interventional

Efficacy, Safety & Tolerability of Switching EFV/TDF/FTC to BIC/FTC/TAF in Virologically Suppressed Adults With HIV-1

NCT03502005
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
bictegravir/emtricitabine/tenofovir alafenamide
Drug
Lead sponsor
Midland Research Group, Inc.
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Oakland Park, Florida
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 14, 2026, 11:23 PM EDT
Completed Phase 4 Interventional Results available

HIV Persistence and Viral Reservoirs

NCT01025427
View directory record Official record
Conditions
HIV, HIV Infections
Interventions
Raltegravir, tenofovir/emtricitabine
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2020 · Synced Oct 14, 2026, 11:23 PM EDT
Completed Phase 3 Interventional Results available

An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)

NCT02831673
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus, HIV Infections
Interventions
Dolutegravir (DTG), Lamivudine (3TC), Tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC FDC)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
719 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
15
States / cities
Phoenix, Arizona • Washington D.C., District of Columbia • Ft. Pierce, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2023 · Synced Oct 14, 2026, 11:23 PM EDT
Terminated Phase 4 Interventional

Testing the Safety and Efficacy of Commercial Drug Biktarvy in Subjects Known to Have the 184 Resistance Mutation to a Component in Biktarvy

NCT04040075
View directory record Official record
Conditions
HIV-1-infection
Interventions
Biktarvy Tab
Drug
Lead sponsor
Southampton Healthcare, Inc.
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 5, 2023 · Synced Oct 14, 2026, 11:23 PM EDT
Recruiting Phase 2 Interventional

A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)

NCT07202546
View directory record Official record
Conditions
HIV Infections
Interventions
VH4524184, Emtricitabine (FTC) and tenofovir alafenamide (TAF) Fixed Dose Combination (FDC) tablets, Dolutegravir / Lamivudine (DTG/3TC)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
34
States / cities
Bakersfield, California • Palm Springs, California • West Hollywood, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 14, 2026, 11:23 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I

NCT02616029
View directory record Official record
Conditions
HIV-1 Infection
Interventions
E/C/F/TAF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
3
States / cities
Ft. Pierce, Florida • Orlando, Florida • West Palm Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jul 23, 2020 · Synced Oct 14, 2026, 11:23 PM EDT